Villers-lès-Nancy,
PRESS RELEASE
H1 2021 Results
- Solid half-year performances with significant contributions from newly acquired companies (PANDALAB and ASCA INFORMATIQUE in 2020, PHARMAGEST SERVIZI in 2021) :
- Revenue: +20.49% to €93.90m
(+10.40% like-for-like)
- Operating Profit: +20.91% to €24.45m
(+10.66% like-for-like)
- Net Profit from Continuing Operations: +30.56% to €17.62m
- Group H2 targets maintained, particularly for earnings.
In €m | H1 2019 | H1 2020 | H1 2021 | Change 2021/2020 |
Revenue | 76.88 | 77.93 | 93.90 | +20.49 % |
Operating Profit | 18.65 | 20.22 | 24.45 | +20.91 % |
Net Profit from Continuing Operations | 13.18 | 13.50 | 17.62 | +30.56 % |
Net Profit | 14.59 | 13.50 | 17.62 | +30.56 % |
The financial statements for the six-month period ended
********
- Results at
30 June 2021
The Group's Operating Profit rose 20.91% to €24.45m at
- Operating Profit for the Europe Pharmacy Solutions Division amounted to €16.15m (+21.53%). The Italy Pharmacy Business Unit registered particularly robust growth with the strengthening of its branch network (creation of PHARMAGEST SERVIZI), the deployment of Easy Pharma (the pharmacy management suite of the subsidiary, SVEMU) and new innovative solutions both for pharmacies (EasyQ, SophiaUp, Miaterapia, etc.) and for wholesaler-distributors (in particular DENSO and Check&Trace). ASCA INFORMATIQUE’s integration into the French Pharmacy Business Unit also had an accretive effect on its operating profit.
- Operating Profit for the Health and Social Care Facilities Solutions Division was €4.69m, up 8.43%. All the Division's businesses are progressing. Strong renewed momentum in the nursing home sector, hit harder by the health crisis, has started to slow down pending the release of public funds expected to be made available by France’s health sector reform (Ségur de la Santé).
- For the e-
Health Solutions and Fintech Divisions, Operating Profit amounted to €3.61m, up 15.65% as the financing market recovered for the Fintech Division.
Net Profit on that basis amounted to €17.62m (+30.56%) and Net Profit Attributable to Equity Holders of the Parent to €16.59m (+31.30%). At
- Consolidated balance sheet highlights
At
Equity attributable to the Parent at
- H1 2021 operating highlights
- Pharmagest Group’s position in the greater
Paris region (Ile-de-France ) strengthened. After previously holding a 50% stake in the capital, the Group has become the sole shareholder of ADI (Applications et Développements Informatiques), its partner-distributor of Group solutions in the greaterParis region for more than 30 years.Pharmagest Group now has a homogeneous regional network of agencies adapted to its business model. The Group will in this way be able to propose pharmacists in the Ile-de-France region its complete catalogue ofPHARMAGEST products and services and support them across the entire business line system it has developed. - Management of the e-Health Solutions Division is strengthened by the addition of Tristan DEBOVE. As Managing Director within the Pharmagest Group’s e-Health Solutions Division, Tristan DEBOVE is responsible for optimising PHARMAGEST’s application ecosystem within French original health boards and regional health networks by leveraging the high degree of interoperability available through the Digital Healthcare Platform. He is also responsible for reinforcing the patient-centred service approach by developing synergies between the Group’s different subsidiaries.
- Launch of the COVID-19 vaccination appointment service.
Pharmagest Group launched PandaLab agenda for pharmacists (a free service integrated in the LGPI pharmacy management application to manage COVID vaccination appointments) and PandaLab Ma Santé for patients (a free app for making vaccination appointments in pharmacies, available on IPhone and Android smartphone). - Strategic partnership with
ELSAN Group . This strategic partnership will accelerate the development inFrance by Pharmagest Group’s subsidiary, PANDALAB, of its secure instant messaging app, Pandalab Pro. Making available Pandalab Pro to ELSAN’s 120 private clinics and hospitals will contribute to Pharmagest Group’s goal of establishing PandaLab Pro as a key tool for communications between all healthcare professionals, whether in private practice, social care establishments or hospitals, inFrance and inEurope .
- Pharmagest Group’s position in the greater
- Significant events occurring after
30 June 2021
After creating the subsidiary PHARMAGEST SERVIZI on
This acquisition has strengthened PHARMAGEST ITALIA's position by completing its range of software solutions for wholesalers-distributors: GoldenPharm@ (ERP management for pharmaceutical wholesalers), Pharm@Comm (communication platform between pharmacies and the pharmaceutical supply chain), and @lberto (a single centralised platform for the management of pharmacy groups).
- H2 2021 outlook
Driven by the recovery of its activities in the H2 2020 and continuing momentum in H1 2021,
In addition, with a positive gross cash position, the Group will continue to focus on restructuring its ecosystem and pursue all market opportunities considered of interest.
The health crisis has made Health a top priority, not only in
Investments announced in connection with French health sector (Ségur de la Santé) and the economic stimulus programmes (“France Relance”) (representing a total budget of €19bn) should accelerate the digital transformation of the healthcare sector to the benefit of the entire range of solutions offered by
Financial calendar:
- Publication of Q3 2021 sales:
10 November 2021 (after the close of trading). - Publication of FY 2021 annual sales:
4 February 2022 (after the close of trading).
About
With more than 1,100 employees acting as “Citizens in the Service of Health and Well-Being”,
As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals,
Listed on Euronext Paris™ - Compartment B
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included under the European Rising Tech label.
Eligible for the “long-only” Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: PMGI FP
For all the latest news go to www.pharmagest.com
Follow
CONTACTS
Analyst and Investor Relations:
Chief Administrative and Financial Officer : Jean-Yves SAMSON
Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@lacooperativewelcoop.com
Media Relations:
FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr
Attachment
- PHARMAGEST_PRESSRELEASE_20210924_H1 2021 RESULTS_en_US
© OMX, source